Sign in
Taking people in United StatesPhase 1/2

Tests RAPA-201 immune cells in adults with solid tumors that stopped responding to immunotherapy

Tests RAPA-201, a patient's own T cells, in adults with advanced solid tumors.

Key facts

Who runs it
Rapa Therapeutics LLC
Where
Hackensack, United StatesSee the site
Trial code
Registry title
RAPA-201 Therapy of Solid Tumors
Status
Recruiting
Phase
Phase 1/2
People taking part
37 people, planned
Started
1 Aug 2021
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • RAPA-201 Rapamycin Resistant T Cells
  • Chemotherapy Prior to RAPA-201 Therapy
  • Pembrolizumab (PD-1 Blocking Antibody)
Record updated
14 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with certain advanced solid tumors that came back or stopped responding after treatment that included an anti-PD-(L)1 antibody.

Age
18 years or older
Sex
All sexes can join
Disease stage
Advanced, metastatic, recurrent tumor that cannot be removed by surgery and has relapsed after at least one earlier line of therapy. Allowed types: head and neck cancer, malignant melanoma, small cell carcinoma, non-small cell lung cancer. Measurable disease is needed.
Earlier treatment
The latest treatment must have included an anti-PD-(L)1 antibody and not worked: no response after at least two cycles, or relapse within 12 months of starting it. People must also have had the standard treatments for their tumor, or refused them in writing.
Biomarker or test result
People whose tumors have gene changes such as BRAF, BRCA, EGFR or ALK must have had targeted therapy, or refused it in writing. A lymphocyte count of at least 300 cells/μL is needed.

Main reasons for not taking part

  • Another active cancer (except non-melanoma skin cancer)
  • Life expectancy under 4 months
  • Pregnant or breastfeeding
  • Cancer spread to the central nervous system that has not been adequately treated
  • Heart attack or stroke within the last 6 months, or severe heart failure (NYHA class III/IV)

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Male or female patients ≥ 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Advanced metastatic, recurrent, and unresectable solid tumor that has relapsed after ≥ one prior line of therapy
  • Subject must have received prior therapy with disease-specific regimens that have been established to convey a clinical benefit. Alternatively, subject must have been offered such regimens and provided written documentation of refusal to receive such regimens
  • Subject with solid tumors with genetic alterations and mutations (including but not limited to BRAF, BRCA, EGFR mutations, and ALK translocations) must have either received targeted therapy for such conditions or provided written documentation of refusal to receive such regimens
  • Exposure to an anti-PD-(L)1 monoclonal antibody therapeutic in the most recent line of prior therapy
  • Documented refractory status to the most recent regimen, which must include an anti-PD-(L)1 monoclonal antibody, as defined by lack of response after at least two cycles of therapy or relapse within 12-months of initiation of anti-PD-(L)1-containing therapy
  • Solid tumor disease types that are eligible for enrollment consist of:; head and neck cancer (squamous cell carcinoma of oral cavity, larynx, nasopharynx, and other sites); malignant melanoma; small cell carcinoma, thoracic and extra-thoracic; and,; non-small cell lung cancer
  • Presence of measurable disease to permit monitoring by RECISTv1.1 Criteria
  • Must have a potential source of autologous T cells potentially sufficient to manufacture RAPA-201 cells, as defined by a circulating absolute lymphocyte count (ALC) of ≥ 300 cells/μL
  • Patients must be ≥ two weeks from last solid tumor cancer chemotherapy, major surgery, radiation therapy and/or participation in investigational trials
  • Patients must have recovered from clinical toxicities (resolution of CTCAE (v5) toxicity to a value of ≤ 2)
  • Ejection fraction (EF) by MUGA or 2-D echocardiogram within institution normal limits, with an EF level of ≥ 40%
  • Calculated creatinine clearance of ≥ 60 mL/min/1.73 m\^2
  • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3 x upper limit of normal
  • ANC (Absolute neutrophil count) of ≥ 1500 cells/μL
  • Platelet count ≥ 100,000 cells/μL
  • Hemoglobin count ≥ 8 grams/μL
  • Bilirubin ≤ 1.5 mg/dL (except if due to Gilbert's disease)
  • Corrected DLCO ≥ 50% (Pulmonary Function Test)
  • No history of abnormal bleeding tendency (as defined by any inherited coagulation defect, or history of internal bleeding)
  • Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care

Who cannot take part

  • Myocardial infarction within 6 months prior to enrollment
  • Other active malignancy (except non-melanoma skin cancer)
  • Seropositivity for HIV, hepatitis B, or hepatitis C, unless such conditions are in stable condition using adequate treatment
  • Uncontrolled hypertension
  • History of cerebrovascular accident within 6 months of enrollment
  • NYHA class III/IV congestive heart failure
  • Uncontrolled angina/ischemic heart disease
  • Cancer metastasis to the central nervous system, unless such metastasis has been adequately treated
  • Patients may be excluded at the discretion of the PI or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk
  • Patients of childbearing age, or males who have a partner of childbearing potential, who are unwilling to practice contraception
  • Life expectancy < 4 months
  • Pregnant or breastfeeding patients

Where in United States

  • Hackensack University Medical CenterHackensack, United StatesContact: Oncology Clinical Research Referral OfficeTaking people

About the trial

What the trial wants to find out

The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of monoclonal antibodies. In this study, the investigators will evaluate the adoptive transfer of RAPA-201 cells, which are checkpoint-deficient polyclonal T cells that represent an analogous yet distinct immune therapy treatment platform for solid tumors. The administration of polyclonal, metabolically-fit RAPA-201 cells is a novel adoptive T cell therapy approach that is suitable for regenerative medicine efforts.

Read full original descriptionShow less

RAPA-201 is a novel immunotherapy product consisting of reprogrammed autologous CD4+ and CD8+ T cells of Th1/Tc1 cytokine phenotype. RAPA-201, which have acquired resistance to the mTOR inhibitor temsirolimus, are manufactured ex vivo from peripheral blood mononuclear cells collected from solid tumor patients using a steady-state apheresis. The novel RAPA-201 manufacturing platform, which incorporates both an mTOR inhibitor (temsirolimus) and an anti-cancer Th1/Tc1 polarizing agent (IFN-alpha) generates polyclonal T cells with five key characteristics:

1. Th1/Tc1: polarization to anti-cancer Th1 and Tc1 subsets, with commensurate down-regulation of immune suppressive Th2 and regulatory T (TREG) subsets; 2. T Central Memory: expression of a T central memory (TCM) phenotype, which promotes T cell engraftment and persistence for prolonged anti-tumor effects; 3. Rapamycin-Resistance: acquisition of rapamycin-resistance, which translates into a multi-faceted anti-apoptotic phenotype that improves T cell fitness in the stringent conditions of the tumor microenvironment; 4. T Cell Quiescence: reduced T cell activation, as evidence by reduced expression of the IL-2 receptor CD25, which reduces T cell-mediated cytokine toxicities such as cytokine-release syndrome (CRS) that limit other forms of T cell therapy; and 5. Reduced Checkpoints: multiple checkpoint inhibitory receptors are markedly reduced on RAPA-201 cells (including but not limited to PD-1, CTLA4, TIM-3, LAG3, and LAIR1), which increases T cell immunity in the checkpoint-replete, immune suppressive tumor microenvironment.

This is a non-randomized, open label, multi-site, phase I/II trial of outpatient RAPA-201 immune T cell therapy in patients with advanced metastatic, recurrent, and unresectable solid tumors that have recurred or relapsed after prior immune therapy. Patients must have tumor relapse after at least one prior line of therapy and must have refractory status to the most recent regimen, which must include an anti-PD-(L)1 monoclonal antibody. Furthermore, accrual focuses upon solid tumor disease types potentially amenable to standard-of-care salvage chemotherapy consisting of the carboplatin + paclitaxel (CP) regimen that will be utilized for host conditioning prior to RAPA-201 therapy. Importantly, carboplatin and paclitaxel are "immunogenic" chemotherapy agents whereby the resultant cancer cell death mechanism is favorable for generation of anti-tumor immune T cell responses. Thus, the CP regimen that this protocol incorporates is intended to directly control tumor progression and indirectly promote anti-tumor T cell immunity.

Protocol therapy consists of six cycles of standard-of-care chemotherapy (carboplatin + paclitaxel (CP) regimen) administered in the outpatient setting every 28 days (chemotherapy administered on cycles day 1, 8, and 15). RAPA-201 cells will be administered at a target flat dose of 400 X 10\^6 cells per infusion on day 3 of cycles 2 through 6.

In the original protocol design, a sample size of up to 22 patients was selected to determine whether RAPA-201 therapy, when used in combination with the CP regimen, represents an active regimen in solid tumors that are resistant to anti-PD(L)-1 checkpoint inhibitor therapy, as defined by a response rate (≥ PR) consistent with a rate of 35%. The first stage of protocol accrual consisted of n=10 patients; to advance to the second protocol accrual stage (accrual of an additional n=12 patients), RAPA-201 therapy must result in a tumor response (≥ PR) in at least 2 out of the 10 initial patients. As described below in the detailed description, this original protocol implementation demonstrated that RAPA-201 represented an active treatment regimen for solid tumor patients, and as such, the protocol was expanded to evaluate the combination of RAPA-201 therapy followed by anti-PD1 maintenance therapy.

The group in the trial

  • Administration of RAPA-201 cellsTreatment being tested

    RAPA-201 cells will be administered at a target flat dose of 400 x 10\^6 cells per infusion. After RAPA-201 therapy, anti-PD1 maintenance therapy (pembrolizumab, 200 mg administered intravenously every 3 weeks for up to 12 months)

    Treatment: RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, and Pembrolizumab (PD-1 Blocking Antibody)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors
Plain-language title
Tests RAPA-201 immune cells in adults with solid tumors that stopped responding to immunotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 May 2025